HomeVideoViaCyte ARM CGMOM 2016

ViaCyte ARM CGMOM 2016

President and CEO of ViaCyte, Dr. Paul Laikind, provides an update on ViaCyte’s two product candidates, PEC-Direct and PEC-Encap, which are novel cell replacement therapies being developed as potential long-term type 1 diabetes treatments to reduce the risk of hypoglycemia and diabetes-related complications. This talk was presented at the 2016 Cell and Gene Meeting on the Mesa.


Previous post
How does sleep effect your risk of developing diabetes
Next post
Arthritis & Diabetes. Testimonials

Leave a Reply

Be the First to Comment!

Notify of